Sidewinder Therapeutics Announces $137 Million Series B Financing to Advance Precision Bispecific ADCs into Clinical Development for Cancer May 21, 2026
Rectify Pharmaceuticals to Present Preclinical Data on New Dual Targeted ABCB4/BSEP Positive Functional Modulator at EASL 2026 May 18, 2026
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones May 14, 2026
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update May 12, 2026
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases May 12, 2026
